Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

Summary

This study is comprised of a main study, an observational study, and optional survey studies. The main study is being done to see whether using Duffy null specific treatment dosing guidelines can reduce or delay dose modifications and avoid neutropenic fever (fever in the setting of low neutrophils) for people with Duffy null phenotype receiving treatment for multiple myeloma or triple negative breast cancer. The observational study is to collect dose modification and neutropenic fever information on patients who do not have the Duffy null phenotype and receive the same standard of care regimens to see if there are differences in dose modifications and neutropenic fever between the two groups. The survey studies seek to understand general health experiences and preferences and experiences specific to people with Duffy null phenotype.

Study Drugs Include:

* Daratumumab
* lenalidomide
* bortezomib
* dexamethasone
* carboplatin
* paclitaxel
* pembrolizumab
* cyclophosphamide
* doxorubicin

Conditions

• Multiple Myeloma
• Triple Negative Breast Cancer
• Duffy Blood Group, Chemokine Receptor Gene Mutation
• Duffy Blood Group, Chemokine Receptor Gene C.-67T>C

Interventions

DRUG

Dexamethasone

Tablet, taken orally

DRUG

Bortezomib

Intravenous infusion

DRUG

LENALIDOMIDE

Tablet, taken orally

DRUG

Daratumumab

Intravenous infusion

DRUG

Carboplatin

Intravenous infusion

DRUG

Paclitaxel

Intravenous infusion

DRUG

Pembrolizumab

Intravenous infusion

DRUG

Cyclophosphamide

Intravenous infusion

DRUG

Doxorubicin

Intravenous infusion

Sponsors & Collaborators

• Andrew Hantel, MD

  lead OTHER

Principal Investigators

• Andrew Hantel, MD · MD

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2026-06-30

Primary Completion

2028-03-31

Completion

2029-03-31

FDA Drug

Yes

Countries

• United States

Study Locations